Other languages Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
30.5 ^USD	-0.07%		+3.74%	-5.57%

Jun. 05	HARMONY Biosciences Presents Positive Data for Pitolisant in the Treatment of Excessive Daytime Sleepiness and FATIGUE in Myotonic Dystrophy Type 1	CI
May. 03	Harmony Biosciences Holdings, Inc. Appoints Kumar Budur as Executive Vice President and Chief Medical & Scientific Officer	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HARMONY Biosciences Presents Positive Data for Pitolisant in the Treatment of Excessive Daytime Sleepiness and FATIGUE in Myotonic Dystrophy Type 1	Jun. 05
Harmony Biosciences Holdings, Inc. Appoints Kumar Budur as Executive Vice President and Chief Medical & Scientific Officer	May. 03
Harmony Biosciences Acquires Epygenix Therapeutics; Shares Rise	Apr. 30
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 30
Harmony Biosciences Holdings, Inc. Reiterates Revenue Guidance for the Year 2024	Apr. 30
Harmony Biosciences, Bioprojet Enter Licensing Deal for Sleep Disorder Therapy	Apr. 11
Harmony Biosciences Begins Phase 3 Trial of Pitolisant to Treat Prader-Willi Syndrome Symptoms	Apr. 03
Harmony Biosciences Initiates Global Phase 3 Registrational Trial (Tempo Study) of Pitolisant in Patients with Prader-Willi Syndrome	Apr. 03
Harmony Biosciences Holdings Insider Sold Shares Worth $383,328, According to a Recent SEC Filing	Mar. 19
Harmony Biosciences Holdings' Q4 Adjusted Net Income Falls, Net Product Revenue Rises; 2024 Revenue Guidance Issued	Feb. 22
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22
Harmony Biosciences Holdings, Inc. Provides Revenue Guidance for the Year 2024	Feb. 22
Harmony Biosciences Says FDA Grants Priority Review for Wakix Supplemental New Drug Application	Feb. 21
U.S. Food and Drug Administration Grants Priority Review to Harmony Biosciences' Application for WAKIX® in Pediatric Narcolepsy	Feb. 21
Harmony Biosciences' Pitolisant Gets FDA's Orphan Drug Designation for Prader-Willi Syndrome	Feb. 20
Harmony Biosciences Preliminary Q4 Results Show "Robust Momentum" for Narcolepsy-Related Drug, Oppenheimer Says	Jan. 10
Harmony Biosciences Reports Higher Preliminary Q4 Revenue; Sets 2024 Revenue Outlook	Jan. 08
Harmony Biosciences Holdings, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year 2023 and for the Year 2024	Jan. 08
Harmony Biosciences Holdings, Inc. Announces Positive Topline Data from Phase 2 Signal Detection Study Evaluating Pitolisant in Adult Patients with Myotonic Dystrophy Type 1	Dec. 07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Other languages

Filters